Endocrine therapy, including the use of Fulvestrant, has been used more than 60 years in clinic for women with ER + endometrial cancer (Battista and Schmidt, 2016; Bogliolo et al., 2017). This evidence concerns the gene ESR1 and endometrial cancer.